Shanghai Microport Medbot (group) Co., Ltd. Class H · HKEX:2252
Shanghai Microport Medbot (group) Co., Ltd. Class H — FY2021 Earnings Presentation
25 slides from Shanghai Microport Medbot (group) Co., Ltd. Class H's earnings presentation, March 2022
Slide 1: 2021 Annual Presentation
2021 Annual Presentation March 2022 Strictly Private and Confidential
Slide 2: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 1
Slide 3: Business highlights in 2021
CONFIDENTIAL Business highlights in 2021 Laparoscopic Orthopedic Toumai®1st received NMPA approval in Jan 2022 Honghu submitted NMPA registration application for TKA in Jul 2021 submitted FDA registration application for TKA in Dec 2021 Toumai®2rd completed enrollment of registrational clinica
Slide 4: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 3
Slide 5: Only surgical robot company world-wide covering all major surgical specialties
CONFIDENTIAL Only surgical robot company world-wide covering all 5 major and fast- growing surgical specialties Laparoscopic Orthopedic Panvascular Natural Orifice Percutaneous China Market US$2,315mm US$451mm US$180mm US$129mm US$264mm Opportunities (2026E) (20A-26E CAGR: 39%) (20A-26E CAGR: 48%) (
Slide 6: Flagship product – Toumai Laparoscopic Surgical Robot
CONFIDENTIAL Laparoscopic surgical robot Flagship product – Toumai® Laparoscopic Surgical Robot Completed the design for Toumai® 2018 1st Generation Toumai® 1st Generation 2018 Admitted to NMPA Green Path First of its kind completed The first Chinese-developed with a Chinese-developed Toumai® May su
Slide 7: Toumai 2nd generation – clinical trial milestone surgeries
Laparoscopic surgical robot (cont’d) CONFIDENTIAL Toumai® 2rd generation – clinical trial milestone surgeries Clinical trial centers coverage First and only domestic 2nd globally & 1st domestic Full application of clinical laparoscopic surgical robot laparoscopic surgical robot to specialties to con
Slide 8: Flagship product – DFVision 3D Electronic Laparoscope
Laparoscopic surgical robot (cont’d) CONFIDENTIAL Flagship product – DFVision® 3D Electronic Laparoscope The first Chinese-developed 3D electronic laparoscope admitted to the NMPA Green Path in Apr 2019 The first surgery completed with Chinese-developed 3D electronic laparoscope in China in Oct
Slide 9: Flagship product – Honghu Orthopedic Surgical Robot
CONFIDENTIAL Orthopedic surgical robot Flagship product – Honghu Orthopedic Surgical Robot The only Chinese-developed joint replacement surgical robot with a self-developed robotic arm. Expected to be the first Chinese-developed surgical robot to obtain FDA approval May Sep Jan Jul Dec Next 2020 202
Slide 10: Natural Orifice Surgical Robot
CONFIDENTIAL Natural Orifice Surgical Robot Trans-bronchial Surgical Robot Robot-assisted natural orifice surgery Surgery application Product Natural orifice surgical robots refer to robots that deliver surgical instruments to the target anatomy through natural pathways of the human body and contr
Slide 11: Panvascular Surgical Robot R-ONE Vascular Interventional Surgical Robot
CONFIDENTIAL Panvascular Surgical Robot R-ONE ® Vascular Interventional Surgical Robot R-ONE® Vascular Robot-assisted Interventional Surgical panvascular surgery Robot (“R-ONE®”) CE Marking Surgery application Product Panvascular surgical robots are used to treat diseases of the vasculature or rel
Slide 12: Percutaneous Surgical Robot Mona Lisa Robotic Transperineal Prostate Biopsy System
CONFIDENTIAL Percutaneous Surgical Robot Mona Lisa Robotic Transperineal Prostate Biopsy System iSR’obotTM Mona Lisa Robotic Robot-assisted Transperineal Prostate Biopsy percutaneous surgeries System (“Mona Lisa”) CE Marking Surgery application Partner/ FDA approval Product Percutaneous surgical r
Slide 13: Cutting-edge technology
CONFIDENTIAL Cutting-edge technology Remote surgery Automatic operation Technology Intelligence image diagnosis – Automatic cutting, diagnosis 5G dedicated network, low delay operation and positioning Multilevel safety mechanism for remote surgery to ensure the Intelligence surgery planning
Slide 14: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 13
Slide 15: Experienced team and well-planned strategies for commercialization
CONFIDENTIAL Experienced team and well-planned strategies for commercialization Specialized Academic promotion / surgeon Increase awareness of surgical Sustainable after-sales commercialization team training and clinical support robots among patients service for hospital 100+ professionals, coveri
Slide 16: Strong industrial operation capabilities for surgical robots
CONFIDENTIAL Strong industrial operation capabilities for surgical robots Largest surgical robot R&D team Most of R&D team members hold a Completed 2 registrational clinical trials for Toumai® and master’s or higher degree Honghu concurrently in China, covering 8 major functions Completed enroll
Slide 17: Clear global vision and established footprint
CONFIDENTIAL Clear global vision and established footprint France-based company providing robotic solutions Singapore-based company to treat vascular diseases which has developed automated China JV shareholding: 51% needle targeting robotics used in percutaneous biopsy China JV shareholding1: 61% Un
Slide 18: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 17
Slide 19: Successful product launch, funding future and adequate cash balance
CONFIDENTIAL Successful product launch, funding future and adequate cash balance Successful product launch Funding future Adequate cash for opportunities Primarily from the sales of DFVision since its approval Net loss of 584.5m with oper. performance loss 1,940.8m at 21YE, YoY 30% by NMPA in Jun 21
Slide 20: Investment on future – Operating Expenses
CONFIDENTIAL Investment on future – Operating Expenses Invest for sustainable growth Prepare for sales ramp-up Support overall business growth R&D Cost S&M Expenses Administrative Expenses (RMB million) (RMB million) (RMB million) SBP SBP SBP 392.6 190% 56.2 107.5 79.2 22.3 135.4 2841% 336.4 12.7 9.
Slide 21: Research and Development Cost
CONFIDENTIAL Research and Development Cost Fund pipeline products Invest in foundation technologies Others Others 22% 23% 392.6m 392.6m Staff Costs 48% Laparoscopic Orthopedic 58% Costs of 19% materials and consumables 28% Laparoscopic: Toumai®1st received NMPA approval in Jan 22; Staff Costs –
Slide 22: Agenda
CONFIDENTIAL Agenda Business Highlights Product Pipeline Update Commercialization Financial Review Appendix 21
Slide 23: Financial Statement – P&L
CONFIDENTIAL Financial Statement – P&L Unit: RMB'000 2021 2020 Var. Revenue 2,150 - Cost of sales (1,231) - Gross profit 919 - Other net income 24,675 9,777 152% Selling and marketing expenses (79,188) (2,693) 2841% Administrative expenses (107,477) (26,884) 300% Research and development costs (392,
Slide 24: Financial Statement – Balance Sheet
CONFIDENTIAL Financial Statement – Balance Sheet Unit: RMB'000 31 Dec 2021 31 Dec 2020 Var. Unit: RMB'000 31 Dec 2021 31 Dec 2020 Var. Non-current assets CAPITAL AND RESERVES Share capital 958,594 900,000 7% Property, plant and equipment 361,000 38,710 833% Reserves 1,434,548 542,856 164% Intangible
Slide 25: Thanks!
MEDBOT™ MecBot Surgical (HRS) (TRS)
Shanghai MicroPort MedBot (Group) — FY2021 Earnings Presentation on 6ix